As described in the results, BC with a TN subtype expressing a higher level of GPR81 tended to exhibit attenuated anti-tumor immune response (lower ratios of CD8/FOXP3) in comparison with that expressing a lower level of GPR81. This evidence concerns the gene FOXP3 and breast cancer.